TLT — Theralase Technologies Balance Sheet
0.000.00%
Last trade - 00:00- CA$41.12m
- CA$41.19m
- CA$1.07m
Annual balance sheet for Theralase Technologies, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 12.5 | 7.88 | 3.71 | 1.65 | 0.318 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.824 | 0.485 | 0.283 | 0.296 | 0.325 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 14.2 | 8.92 | 5 | 2.5 | 1.5 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.15 | 1.04 | 0.866 | 1.11 | 0.858 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 15.5 | 10 | 5.94 | 4.16 | 3.28 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.52 | 0.821 | 0.875 | 0.681 | 1.08 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 1.61 | 0.857 | 0.875 | 1.07 | 1.37 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 13.9 | 9.16 | 5.07 | 3.09 | 1.91 |
| Total Liabilities & Shareholders' Equity | 15.5 | 10 | 5.94 | 4.16 | 3.28 |
| Total Common Shares Outstanding |